Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes

Background  Transfusion‐related morbidity is an emerging problem in chronically transfused patients with myelodysplastic syndromes (MDS). Although several iron‐chelating drugs are available, the optimal way of treatment of iron‐overload remains uncertain. A major disadvantage of deferoxamine is that the drug has to be applied as continuous subcutaneous infusion. Therefore, novel oral agents have been developed. One of these drugs is deferasirox (Exjade®).

[1]  P. Nguyen,et al.  Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.

[2]  R. Hehlmann,et al.  Deferasirox in MDS patients with transfusion-caused iron overload—a phase-II study , 2009, Annals of Hematology.

[3]  J. Bennett.  Consensus statement on iron overload in myelodysplastic syndromes , 2008, American journal of hematology.

[4]  D. Cilloni,et al.  Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary Myelofibrosis , 2008, Acta Haematologica.

[5]  B. Leber,et al.  Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. , 2008, Leukemia research.

[6]  N. Gattermann.  Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload , 2008, International journal of hematology.

[7]  Rainer Haas,et al.  Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes , 2008, Annals of Hematology.

[8]  P. Valent,et al.  Iron overload in myelodysplastic syndromes (MDS) – diagnosis, management, and response criteria: a proposal of the Austrian MDS platform , 2008, European journal of clinical investigation.

[9]  M. Cazzola,et al.  Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study , 2007, European journal of haematology.

[10]  J. Maciejewski,et al.  Hemochromatosis‐associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts , 2007, American journal of hematology.

[11]  M. Tomonaga,et al.  Retrospective nationwide survey of Japanese patients with transfusion‐dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality , 2007, European journal of haematology.

[12]  T. Haferlach,et al.  Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. , 2007, Leukemia research.

[13]  A. Tordai,et al.  The significance of the hemochromatosis genetic variants in multiple myeloma in comparison to that of myelodysplastic syndrome , 2006, Annals of Hematology.

[14]  S. Perrotta,et al.  A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. , 2006, Blood.

[15]  P. Greenberg.  Myelodysplastic syndromes: iron overload consequences and current chelating therapies. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[16]  J. Bennett,et al.  The myelodysplastic syndromes: Diagnosis, molecular biology and risk assessment , 2005, Hematology.

[17]  C. Hershko.  Treating iron overload: the state of the art. , 2005, Seminars in hematology.

[18]  A. Tordai,et al.  High Incidence of Hemochromatosis Gene Mutations in the Myelodysplastic Syndrome: The Budapest Study on 50 Patients , 2003, Acta Haematologica.

[19]  I. Cabantchik,et al.  Objectives and Methods of Iron Chelation Therapy , 2003, Bioinorganic chemistry and applications.

[20]  P. Fenaux,et al.  Surcharge martiale et syndromes myélodysplasiques (SMD) , 2001 .

[21]  P. Fenaux,et al.  [Iron overload and myelodysplastic syndromes]. , 2001, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[22]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[23]  F. Jensen,et al.  The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload , 1996, British journal of haematology.

[24]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.